Company intelligence / Profile preview

NuGenerex Immuno-Oncology

Miramar, Florida, United Statesnugenerexinc.com ↗

Ownership: Private
Employees: ~6
Development stage: Phase 2

Overview

AE37 (lead product) has shown promising results in Phase II trials for breast cancer, particularly in patients with advanced stage, HER2 under-expression, and triple negative breast cancer. The vaccine demonstrated improved disease-free survival for up to ten years of follow-up. Currently in Phase II trials for metastatic triple negative breast cancer in combination with pembrolizumab (Keytruda).

Therapeutic areas: OncologyInfectious Diseases
Modalities: Immunotherapeutic peptide vaccines
Industry: Biotech

Drug pipeline

4 assets

AE37

3 more assets in the full pipeline.

Request access →

Partnerships

Merck Sharpe & Dohme Corp.National Surgical Adjuvant Breast and Bowel Program (NSABP)Shenzhen Bioscien (China)

Beyond the preview

Go deeper on NuGenerex Immuno-Oncology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NuGenerex Immuno-Oncology.

Explore the full profile